Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04418297 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
A Phase 1 study, sponsored by Celltrion.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04418297 is a Phase 1 study that was terminated before completion, run by Celltrion. The registered enrollment target is 23 participants.
The verdict
NCT04418297, a Phase 1 study, was terminated before completion, sponsored by Celltrion.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, sequential, 5-day treatment, ascending dose study in subjects with obstructive HCM aged 18-70 years. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-G20.
Interventions
- DRUG Placebo
- DRUG CT-G20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2022-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04418297
The ClinicalTrials.gov registry entry for NCT04418297 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celltrion, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04418297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04418297 about?
NCT04418297 is a clinical study titled "A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy". This is a randomized, double-blind, placebo-controlled, sequential, 5-day treatment, ascending dose study in subjects with obstructive HCM aged 18-70 years. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-G20.
What is the current status of trial NCT04418297?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2020-10-23. Estimated completion is 2022-11-22.
What interventions are being tested in trial NCT04418297?
The interventions under investigation include: Placebo (DRUG), CT-G20 (DRUG).
Who is sponsoring clinical trial NCT04418297?
This trial is sponsored by Celltrion, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.